21/02/2024 - Press release
This is an international collaborative work coordinated by the Hospital del Mar Research Institut and the Hospital Clínic-IDIBAPS, published in the Journal of Neurology. This new tool may make it possible to adapt the monitoring and treatment of patients to their future evolution, opting for the most effective, but with more possible side effects in those with worse prognosis. The exact factors behind the progression of disability in multiple sclerosis, a disease with great heterogeneity, are unknown, which is why it is so important to have tools of this type.
20/02/2024 - General information
He does so as a Reference Researcher, the highest possible category. A fact that recognizes his research activity in recent years. Dr. Daniel Guinart, consultant psychiatrist at the Psychosocial Rehabilitation and Treatment-Resistant Schizophrenia Unit of the Hospital del Mar and researcher at its research institute, has achieved the category of Reference Researcher of the Sociedad Española de Psiquiatría y Salud Mental (SEPSM). This recognition of his work is part of the Research Excellence Program of the organization.
19/02/2024 - General information
The Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program will finance this new phase. It will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with SXF, the most common form of hereditary intellectual disability without specific treatment. The public-private consortium formed by the biotechnology company CONNECTA Therapeutics, the Hospital del Mar Research Institute, the Center for Genomic Regulation (CRG), and the Parc Taulí Research and Innovation Institute (I3PT) will receive 2,7 million euros in funding from the Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program, to initiate Phase IIa clinical trials of the drug CTH120 for the treatment of Fragile X syndrome (Fragile X syndrome).
Més informació "Nearly 3 million euros to initiate Phase IIa of CTH120 drug for Fragile X syndrome"
16/02/2024 - Events
From March 4 to May 13, 2024, will take place in different libraries of Barcelona the cycle "What do we know about heart diseases", organized by Hospital del Mar Research Institute and the Network of Libraries of Barcelona. This is a cycle that is part of the "Visions of Science" project that the Barcelona Libraries have been carrying out for years, and that for the fourth year has been entrusted to the Hospital del Mar Research Institute thanks to the success obtained in previous editions.
15/02/2024 - Press release
A study by Hospital del Mar and Hospital General de Catalunya shows that this new type of device is three times more effective than previous models in completely closing the aneurysm. Moreover, in a safe way. It is published in the Journal of Neurointerventional Surgery. The new generation of stents for the treatment of cerebral aneurysms is more effective and safer, according to a study by Hospital del Mar and Hospital General de Catalunya that has just been published in the Journal of Neurointerventional Surgery. In fact, they are three times more effective, with practically no complications.
Més informació "Efficacy of the new generation of stents to treat cerebral aneurysm validated"
14/02/2024 - Covid-19
It is a monoclonal antibody with prophylactic and therapeutic action, isolated from blood samples of a patient infected by SARS-CoV-2 during the first wave of the pandemic. The antibody has been designed and developed by researchers from the Hospital del Mar Research Institute, the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology and the Center for Genomic Regulation. In addition, this new treatment has been patented pending commercial development. This new treatment has been patented pending commercial development. The results of the work have been published in the journal Nature Communications.
Més informació "New antibody blocks all SARS-CoV-2 variants in preclinical models"
09/02/2024 - Press release
An international study has used a computational biology tool that, by analysing a multitude of biological data from multiple sclerosis patients ranging from genetic information to the whole organism, reveals the relationship between elements of different biological scales and improves our knowledge and the diagnosis of the disease. International research led by the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University, in collaboration with Hospital del Mar, Hospital Clínic, Charité - Medical University of Berlin, and the universities of Oslo and Genoa, has developed a computational biology tool, based on multi-level network analysis, to achieve an integrated vision of multiple sclerosis. This tool could be used to study other complex diseases such as types of dementia.
07/02/2024 - Institutional news
The Carlos III Health Institute has approved the renewal of this accreditation, first achieved in 2013. On January 30, the Carlos III Health Institute approved the renewal of the Hospital del Mar Research Institute's accreditation as a Health Research Institute. The center thus passes, for the second time, the audit required to maintain this accreditation, which it received for the first time in 2013.
06/02/2024 - General information
Sociodemographic, epidemiological, technological and societal demand changes make it necessary to face a transformation of the health system in order to promote both its own sustainability and the improvement of expected health outcomes. In order to carry out this transformation, long term strategies are needed, which go beyond the cycles of government, as well as the commitment between the different agents that have influence there. For this reason, it is considered necessary to do so through a National Health Pact.
Més informació "Citizen Participation Process in the National Health Pact"
02/02/2024 - Institutional news
The laboratory director, Dr. Rosa Ventura Alemany, has been invited to join different expert committees of the agency starting this year. Dr. Ventura will be a member of the expert committee of anti-doping laboratories, which has the function of managing and monitoring the accreditation of laboratories and updating the regulations of the World Anti-Doping Agency (WADA). In addition, she will also be a member of the working group on the use of dried blood spots (DBS) in doping controls and of the MRPL (minimum required performance levels) working group, which defines the detection limits that laboratories have to achieve for the different substances prohibited in sport in order to perform effective doping controls.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact